51. Scleroderma Clinical trials / Disease details
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05204355 (ClinicalTrials.gov) | May 1, 2022 | 10/1/2022 | MRI for Screening and Monitoring Scleroderma ILD | MRI for Screening and Monitoring Systemic Sclerosis Interstitial Lung Disease | Scleroderma | Diagnostic Test: MRI;Drug: Hyperpolarized Xe129;Diagnostic Test: HRCT | University of Kansas Medical Center | Scleroderma Foundation | Recruiting | 18 Years | N/A | All | 42 | United States |